Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 25,101 shares of Stemline Therapeutics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $278,872.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Thursday, March 7th, Kenneth Hoberman sold 2,995 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.36, for a total transaction of $34,023.20.
  • On Monday, February 25th, Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock. The stock was sold at an average price of $12.05, for a total transaction of $127,211.85.
  • On Tuesday, January 8th, Kenneth Hoberman sold 13,547 shares of Stemline Therapeutics stock. The stock was sold at an average price of $10.15, for a total transaction of $137,502.05.

NASDAQ STML opened at $13.62 on Friday. The firm has a market cap of $433.13 million, a PE ratio of -4.63 and a beta of 1.12. Stemline Therapeutics Inc has a one year low of $7.82 and a one year high of $20.55.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Stemline Therapeutics by 10.8% during the 4th quarter. Geode Capital Management LLC now owns 311,327 shares of the biopharmaceutical company’s stock worth $2,956,000 after purchasing an additional 30,324 shares during the period. Dimensional Fund Advisors LP raised its stake in Stemline Therapeutics by 8.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 185,395 shares of the biopharmaceutical company’s stock valued at $1,761,000 after acquiring an additional 14,275 shares during the period. Millennium Management LLC raised its stake in Stemline Therapeutics by 106.0% in the 4th quarter. Millennium Management LLC now owns 305,176 shares of the biopharmaceutical company’s stock valued at $2,899,000 after acquiring an additional 157,031 shares during the period. Legal & General Group Plc raised its stake in Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,120 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its stake in Stemline Therapeutics by 327.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 6,527 shares during the period. Institutional investors own 64.82% of the company’s stock.

STML has been the topic of a number of recent analyst reports. Piper Jaffray Companies reiterated an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 26th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Finally, BidaskClub cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 29th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $25.40.

ILLEGAL ACTIVITY WARNING: “Kenneth Hoberman Sells 25,101 Shares of Stemline Therapeutics Inc (STML) Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/kenneth-hoberman-sells-25101-shares-of-stemline-therapeutics-inc-stml-stock/2896777.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Read More: How Do Front-End Loads Impact an Investment?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.